A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

NCT05377333 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of a new medication called LY3457263, both on its own and when combined with dulaglutide, in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 94 people

Who can join Ages 20–75 · all sexes

Timeline Started 2022-06 · est. completion 2023-11

Where 5 sites · United States

What this study is testing ClinicalTrials.gov NCT05377333 ↗

Description as written by the study sponsor.

The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 when administered alone or in combination with glucagon-like peptide 1 (GLP-1) receptor agonist (RA) in participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to approximately 16 weeks excluding the screening period for each participant and include up to 17 visits.

Treatments tested

LY3457263 Drug

Administered SC.
Placebo Drug

Administered SC.
Dulaglutide also known as LY2189265 Drug

Administered SC.

Main thing measured	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05377333 ↗